VERU VERU INC.
Updated
Healthcare · Pharmaceutical Preparations
VERU INC. (VERU) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $45 million. Shares last traded at $2.65, 63.6% below their 52-week high. Over the past year the stock is down 20.3%. Net profit margin is -80.6%, below the peer median of -8.9%. Revenue grew 3.6% year over year. The shares yield 21.1% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
VERU Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2015-09-30 | $0M | $0.00 | 0% |
| 2014-09-30 | $6M | $0.21 | 250% |
| 2013-09-30 | $7M | $0.26 | 52% |
| 2012-09-30 | $6M | $0.22 | 40% |
| 2011-09-30 | $6M | $0.20 | 103% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2024 | $-0.15 | 2024-05-08 |
| Q1 2024 | $-0.08 | 2024-04-01 |
| FY 2023 | $-1.10 | 2023-12-08 |
| Q3 2023 | $-0.83 | 2023-08-10 |
| Q2 2024 | $-0.90 | 2024-05-08 |
| Q1 2024 | $-0.48 | 2024-04-01 |
Pharmaceutical Preparations peers
VERU vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.